Prostate cancer will become an epidemic male health problem due to increasing life expectancy. There is a critical need for accurate imaging evaluation of patients with metastatic prostate cancer. Positron emission tomography (PET) with the most common tracer currently available, [F-18]-fluorodeoxyglucose (FDG), has emerged as an important diagnostic imaging modality in cancer. Recent advances in imaging technology have also resulted in dual-modality PET-CT systems that allow precise fusion of anatomic and metabolic imaging data. Our preliminary in-vitro cell culture, animal in-vivo, and pilot clinical studies have provided compelling evidence that FDG PET may have a significant role in the imaging evaluation of patients with metastatic prostate cancer. There are two specific aims for this research proposal: 1) to assess the diagnostic utility of FDG PET-CT in the evaluation of therapy response in two clinically distinct groups of patients with metastatic prostate cancer, Group I: men with newly diagnosed hormone-naive metastatic disease who will be treated with the standard androgen ablation therapy, and Group II: men with newly developed hormone-refractory metastatic cancer who will be treated with standard chemotherapy, and 2) to evaluate FDG PET-CT in predicting patient outcome. We hypothesize that semi-quantitative FDG PET-CT monitoring of the serial changes in the glucose metabolism of metastatic prostate cancer lesions provides a competitive advantage over the conventional methods in the objective assessment of treatment response and in predicting key clinical outcomes. To test this hypothesis, we will perform a prospective cohort study to evaluate the diagnostic and prognostic utility of serial FDG PET-CT imaging in determining tumor metabolic response to either androgen ablation therapy or to chemotherapy and in predicting key clinical outcomes such as time to hormone-refractory state and survival. Rigorous statistical methods will be applied to determine the diagnostic and prognostic performance of FDG PET-CT in this clinical setting. ? ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Medical Imaging Study Section (MEDI)
Program Officer
Shankar, Lalitha K
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Schools of Medicine
Los Angeles
United States
Zip Code
Jadvar, Hossein; Chen, Xiaoyuan; Cai, Weibo et al. (2018) Radiotheranostics in Cancer Diagnosis and Management. Radiology 286:388-400
Chau, Albert; Gardiner, Peter; Colletti, Patrick M et al. (2018) Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases. Clin Nucl Med 43:e226-e231
Jadvar, Hossein (2017) Highlights of articles published in annals of nuclear medicine 2016. Eur J Nucl Med Mol Imaging 44:1928-1933
Jadvar, Hossein; Park, Ryan; Yap, Li-Peng et al. (2017) Effect of Androgen on Normal Biodistribution of [18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in Athymic Non-tumor-bearing Male Mice. Anticancer Res 37:475-479
Jadvar, Hossein (2017) Multimodal Imaging in Focal Therapy Planning and Assessment in Primary Prostate Cancer. Clin Transl Imaging 5:199-208
Jadvar, Hossein (2017) Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. AJR Am J Roentgenol 209:277-288
Jadvar, Hossein (2016) Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer. Abdom Radiol (NY) 41:889-98
Iagaru, Andrei H; Mittra, Erik; Colletti, Patrick M et al. (2016) Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer. J Nucl Med 57:19S-24S
Jadvar, Hossein (2016) Radiotheranostics in Prostate Cancer: Introduction and Overview. J Nucl Med 57:1S-2S
Jadvar, Hossein (2016) Is There Use for FDG-PET in Prostate Cancer? Semin Nucl Med 46:502-506

Showing the most recent 10 out of 43 publications